<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">MD-Onco</journal-id><journal-title-group><journal-title xml:lang="en">MD-Onco</journal-title><trans-title-group xml:lang="ru"><trans-title>MD-Onco</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2782-3202</issn><issn publication-format="electronic">2782-6171</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">119</article-id><article-id pub-id-type="doi">10.17650/2782-3202-2024-4-2-87-92</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>SUPPORTING THERAPY ASPECTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>АСПЕКТЫ ПОДДЕРЖИВАЮЩЕЙ ТЕРАПИИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Modulation of the intestinal microbiota as a new strategy for the prevention and treatment of comorbid chronic cardiovascular diseases and colorectal cancer in one patient. Review</article-title><trans-title-group xml:lang="ru"><trans-title>Модуляция кишечной микробиоты как новая стратегия профилактики и лечения коморбидных хронических сердечно-сосудистых заболеваний и колоректального рака у одного пациента. Обзор литературы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2075-8543</contrib-id><name-alternatives><name xml:lang="en"><surname>Frolova</surname><given-names>Yu. V.</given-names></name><name xml:lang="ru"><surname>Фролова</surname><given-names>Ю. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><bold>Yulia V. Frolova </bold></p><p><italic>2 Abrikosovsky Ln., Moscow 19991</italic></p></bio><bio xml:lang="ru"><p><bold>Юлия Валерьевна Фролова </bold></p><p><italic>119991 Москва, Абрикосовский пер., 2</italic></p></bio><email>julrab@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3624-4774</contrib-id><name-alternatives><name xml:lang="en"><surname>Dymova</surname><given-names>O. V.</given-names></name><name xml:lang="ru"><surname>Дымова</surname><given-names>О. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>2 Abrikosovsky Ln., Moscow 19991</italic></p></bio><bio xml:lang="ru"><p><italic>119991 Москва, Абрикосовский пер., 2</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1705-928X</contrib-id><name-alternatives><name xml:lang="en"><surname>Petrenko</surname><given-names>K. N.</given-names></name><name xml:lang="ru"><surname>Петренко</surname><given-names>К. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>2 Abrikosovsky Ln., Moscow 19991</italic></p></bio><bio xml:lang="ru"><p><italic>119991 Москва, Абрикосовский пер., 2</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5165-1204</contrib-id><name-alternatives><name xml:lang="en"><surname>Tsatsurova</surname><given-names>S. A.</given-names></name><name xml:lang="ru"><surname>Цацурова</surname><given-names>С. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>2 Abrikosovsky Ln., Moscow 19991</italic></p></bio><bio xml:lang="ru"><p><italic>119991 Москва, Абрикосовский пер., 2</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4377-0035</contrib-id><name-alternatives><name xml:lang="en"><surname>Bedzhanyan</surname><given-names>A. L.</given-names></name><name xml:lang="ru"><surname>Беджанян</surname><given-names>А. Л.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>2 Abrikosovsky Ln., Moscow 19991</italic></p></bio><bio xml:lang="ru"><p><italic>119991 Москва, Абрикосовский пер., 2</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">B.V. Petrovsky Russian Scientific Centre of Surgery</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Российский научный центр хирургии им. акад. Б.В. Петровского»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-06-14" publication-format="electronic"><day>14</day><month>06</month><year>2024</year></pub-date><volume>4</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>87</fpage><lpage>92</lpage><history><date date-type="received" iso-8601-date="2024-06-14"><day>14</day><month>06</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-06-14"><day>14</day><month>06</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, ABV-Press</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, АБВ-пресс</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">ABV-Press</copyright-holder><copyright-holder xml:lang="ru">АБВ-пресс</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://mdonco.abvpress.ru/jour/about/editorialPolicies</ali:license_ref></license></permissions><self-uri xlink:href="https://mdonco.abvpress.ru/jour/article/view/119">https://mdonco.abvpress.ru/jour/article/view/119</self-uri><abstract xml:lang="en"><p>To date, the etiological causes of adverse outcomes associated with cardiovascular diseases and concomitant colorectal cancer in one patient, especially over 60 years of age, are multifactorial: from undiagnosed timely above-mentioned pathological conditions to poor adherence to treatment. It is a multi-level approach that is the future guarantee of reducing the burden on public health as a result of these most common nosologies.</p><p>The aim of the work is to evaluate discussions between different experts with an analysis of fundamental and clinical studies based on world literature in the search for new prospects for the treatment of patients with cardiovascular pathology and comorbid colorectal cancer based on the composition and function of the intestinal microbiota.</p><p>A literature search was conducted in the PubMed electronic database using the keywords: intestinal microbiota, cardio-oncology, oncosurgery, colorectal cancer, cardiovascular diseases. Additional sources were identified through literature cross-referencing. Search period: 2023.</p><p>The gut microbiome is a potential marker for better risk stratification of cardiovascular diseases, colorectal cancer, and prediction of shortand long-term major adverse cardiovascular and cancer events. To develop clear recommendations and conclusions, additional research is required.</p></abstract><trans-abstract xml:lang="ru"><p>На сегодняшний день этиологические причины неблагоприятных исходов, связанных с сердечно-сосудистыми заболеваниями и сопутствующим колоректальным раком у одного пациента, особенно старше 60 лет, многофакторны: от недиагностированных своевременно вышеуказанных патологических состояний до плохой приверженности лечению. Именно многоуровневый подход является будущей гарантией снижения нагрузки на общественное здравоохранение, связанной с этими наиболее часто встречаемыми нозологиями.</p><p>Цель работы – на основании данных мировой литературы проанализировать дискуссии между разными экспертами, результаты фундаментальных и клинических исследований в поиске новых перспектив лечения пациентов с сердечно-сосудистой патологией и коморбидным колоректальным раком на основании состава и функции кишечной микробиоты.</p><p>Поиск литературы проводился в электронной базе PubMed с использованием ключевых слов: intestinal microbiota, cardiooncology, oncosurgery, colorectal cancer, cardiovascular diseases. Дополнительные источники были найдены по перекрестным ссылкам литературы. Период поиска – 2023 г.</p><p>Микробиом кишечника является потенциальным маркером для лучшей стратификации рисков сердечно-сосудистых заболеваний, колоректального рака и прогнозирования краткосрочных и долгосрочных серьезных неблагоприятных сердечно-сосудистых и онкологических событий. Однако для разработки однозначных рекомендаций и выводов требуется проведение дополнительных исследований.</p></trans-abstract><kwd-group xml:lang="en"><kwd>intestinal microbiota</kwd><kwd>cardio-oncology</kwd><kwd>oncosurgery</kwd><kwd>colorectal cancer</kwd><kwd>cardiovascular diseases</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>микробиота кишечника</kwd><kwd>кардиоонкология</kwd><kwd>онкохирургия</kwd><kwd>колоректальный рак</kwd><kwd>сердечно-сосудистые заболевания</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The study was conducted with the support of the Ministry of Education and Science of Russia (FURG-2023-0002)</funding-statement><funding-statement xml:lang="ru">Исследование проведено при поддержке Минобрнауки России (FURG-2023-0002)</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Shimizu Y. Gut microbiota in common elderly diseases affecting activities of daily living. World J Gastroenterol 2018;24(42):4750–8; DOI: 10.3748/wjg.v24.i42.4750</mixed-citation><mixed-citation xml:lang="ru">Shimizu Y. Gut microbiota in common elderly diseases affecting activities of daily living. World J Gastroenterol 2018;24(42):4750–8; DOI: 10.3748/wjg.v24.i42.4750</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Nouri R., Hasani A., Asgharzadeh M. et al. Roles of gut microbiota in colorectal carcinogenesis providing a perspective for early diagnosis and treatment. Curr Pharm Biotechnol 2022;23(13):1569–80. DOI: 10.2174/1389201023666220307112413</mixed-citation><mixed-citation xml:lang="ru">Nouri R., Hasani A., Asgharzadeh M. et al. Roles of gut microbiota in colorectal carcinogenesis providing a perspective for early diagnosis and treatment. Curr Pharm Biotechnol 2022;23(13):1569–80. DOI: 10.2174/1389201023666220307112413</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Alasiri G.A. Effect of gut microbiota on colorectal cancer progression and treatment. Saudi Med J 2022;43(12):1289–99. DOI: 10.15537/smj.2022.43.12.20220367</mixed-citation><mixed-citation xml:lang="ru">Alasiri G.A. Effect of gut microbiota on colorectal cancer progression and treatment. Saudi Med J 2022;43(12):1289–99. DOI: 10.15537/smj.2022.43.12.20220367</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70(1):7–30. DOI: 10.3322/caac.21590</mixed-citation><mixed-citation xml:lang="ru">Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70(1):7–30. DOI: 10.3322/caac.21590</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Kim H., Park I.J., Han Y. et al. Cardiovascular morbidities in postoperative colorectal cancer patients. Sci Rep 2021;11(1):21359. DOI: 10.1038/s41598-021-00735-3</mixed-citation><mixed-citation xml:lang="ru">Kim H., Park I.J., Han Y. et al. Cardiovascular morbidities in postoperative colorectal cancer patients. Sci Rep 2021;11(1):21359. DOI: 10.1038/s41598-021-00735-3</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Alam M.J., Puppala V., Uppulapu S.K. et al. Human microbiome and cardiovascular diseases. Prog Mol Biol Transl Sci 2022;192(1):231–79. DOI: 10.1016/bs.pmbts.2022.07.012</mixed-citation><mixed-citation xml:lang="ru">Alam M.J., Puppala V., Uppulapu S.K. et al. Human microbiome and cardiovascular diseases. Prog Mol Biol Transl Sci 2022;192(1):231–79. DOI: 10.1016/bs.pmbts.2022.07.012</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Shelton C.D., Byndloss M.X. Gut epithelial metabolism as a key driver of intestinal dysbiosis associated with noncommunicable diseases. Infect Immun 2020;88(7):e00939–19. DOI: 10.1128/IAI.00939-19</mixed-citation><mixed-citation xml:lang="ru">Shelton C.D., Byndloss M.X. Gut epithelial metabolism as a key driver of intestinal dysbiosis associated with noncommunicable diseases. Infect Immun 2020;88(7):e00939–19. DOI: 10.1128/IAI.00939-19</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Soerjomataram I., Bray F. Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070. Nat Rev Clin Oncol 2021;18(10):663–72. DOI: 10.1038/s41571-021-00514-z</mixed-citation><mixed-citation xml:lang="ru">Soerjomataram I., Bray F. Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070. Nat Rev Clin Oncol 2021;18(10):663–72. DOI: 10.1038/s41571-021-00514-z</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Siegel R.L., Miller K.D., Wagle N.S., Jemal A. Cancer statistics, 2023. CA A Cancer J Clin 2023;73(1);17–48. DOI: 10.3322/caac.21763</mixed-citation><mixed-citation xml:lang="ru">Siegel R.L., Miller K.D., Wagle N.S., Jemal A. Cancer statistics, 2023. CA A Cancer J Clin 2023;73(1);17–48. DOI: 10.3322/caac.21763</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Huo R.X., Wang Y.J., Hou S.B. et al. Gut mucosal microbiota profiles linked to colorectal cancer recurrence. World J Gastroenterol 2022;28(18):1946–64. DOI: 10.3748/wjg.v28.i18.1946</mixed-citation><mixed-citation xml:lang="ru">Huo R.X., Wang Y.J., Hou S.B. et al. Gut mucosal microbiota profiles linked to colorectal cancer recurrence. World J Gastroenterol 2022;28(18):1946–64. DOI: 10.3748/wjg.v28.i18.1946</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Xia C., Cai Y., Ren S., Xia C. Role of microbes in colorectal cancer therapy: cross-talk between the microbiome and tumor microenvironment. Front Pharmacol 2022;13:1051330. DOI: 10.3389/fphar.2022.1051330</mixed-citation><mixed-citation xml:lang="ru">Xia C., Cai Y., Ren S., Xia C. Role of microbes in colorectal cancer therapy: cross-talk between the microbiome and tumor microenvironment. Front Pharmacol 2022;13:1051330. DOI: 10.3389/fphar.2022.1051330</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Fong W., Li Q., Yu J. Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer. Oncogene 2020;39(26):4925–43. DOI: 10.1038/s41388-020-1341-1</mixed-citation><mixed-citation xml:lang="ru">Fong W., Li Q., Yu J. Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer. Oncogene 2020;39(26):4925–43. DOI: 10.1038/s41388-020-1341-1</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. Fabbri A., Bracci L. Immunomodulatory properties of CNF1 toxin from E. coli: implications for colorectal carcinogenesis. Am J Cancer Res 2022;12(2):651–60.</mixed-citation><mixed-citation xml:lang="ru">Fabbri A., Bracci L. Immunomodulatory properties of CNF1 toxin from E. coli: implications for colorectal carcinogenesis. Am J Cancer Res 2022;12(2):651–60.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Wong S.H., Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat Rev Gastroenterol Hepatol 2019;16(11):690–704. DOI: 10.1038/s41575-019-0209-8</mixed-citation><mixed-citation xml:lang="ru">Wong S.H., Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat Rev Gastroenterol Hepatol 2019;16(11):690–704. DOI: 10.1038/s41575-019-0209-8</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Shi Y., Cui H., Wang F. et al. Role of gut microbiota in postoperative complications and prognosis of gastrointestinal surgery: a narrative review. Medicine (Baltimore) 2022;101(29):e29826. DOI: 10.1097/MD.0000000000029826</mixed-citation><mixed-citation xml:lang="ru">Shi Y., Cui H., Wang F. et al. Role of gut microbiota in postoperative complications and prognosis of gastrointestinal surgery: a narrative review. Medicine (Baltimore) 2022;101(29):e29826. DOI: 10.1097/MD.0000000000029826</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16. Lucafò M., Curci D., Franzin M. et al. Inflammatory bowel disease and risk of colorectal cancer: an overview from pathophysiology to pharmacological prevention. Front Pharmacol 2021;12:772101. DOI: 10.3389/fphar.2021.772101</mixed-citation><mixed-citation xml:lang="ru">Lucafò M., Curci D., Franzin M. et al. Inflammatory bowel disease and risk of colorectal cancer: an overview from pathophysiology to pharmacological prevention. Front Pharmacol 2021;12:772101. DOI: 10.3389/fphar.2021.772101</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17. Popov J., Caputi V., Nandeesha N. et al. Microbiota-immune interactions in ulcerative colitis and colitis associated cancer and emerging microbiota-based therapies. Int J Mol Sci 2021;22. DOI: 10.3390/ijms222111365</mixed-citation><mixed-citation xml:lang="ru">Popov J., Caputi V., Nandeesha N. et al. Microbiota-immune interactions in ulcerative colitis and colitis associated cancer and emerging microbiota-based therapies. Int J Mol Sci 2021;22. DOI: 10.3390/ijms222111365</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18. Yu L.C. Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground hypothesis. J Biomed Sci 2018;25(1):79. DOI: 10.1186/s12929-018-0483-8</mixed-citation><mixed-citation xml:lang="ru">Yu L.C. Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground hypothesis. J Biomed Sci 2018;25(1):79. DOI: 10.1186/s12929-018-0483-8</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19. Yang Y., Gharaibeh R.Z., Newsome R.C., Jobin C. Amending microbiota by targeting intestinal inflammation with TNF blockade attenuates development of colorectal cancer. Nat Cancer 2020;1(7):723–34. DOI: 10.1038/s43018-020-0078-7</mixed-citation><mixed-citation xml:lang="ru">Yang Y., Gharaibeh R.Z., Newsome R.C., Jobin C. Amending microbiota by targeting intestinal inflammation with TNF blockade attenuates development of colorectal cancer. Nat Cancer 2020;1(7):723–34. DOI: 10.1038/s43018-020-0078-7</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">20. Zamani S., Taslimi R., Sarabi A. et al. Enterotoxigenic Bacteroides fragilis: a possible etiological candidate for bacterially-induced colorectal precancerous and cancerous lesions. Front Cell Infect Microbiol 2019;9:449. DOI: 10.3389/fcimb.2019.00449</mixed-citation><mixed-citation xml:lang="ru">Zamani S., Taslimi R., Sarabi A. et al. Enterotoxigenic Bacteroides fragilis: a possible etiological candidate for bacterially-induced colorectal precancerous and cancerous lesions. Front Cell Infect Microbiol 2019;9:449. DOI: 10.3389/fcimb.2019.00449</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">21. Quaglio A.E.V., Grillo T.G., De Oliveira E.C.S. et al. Gut microbiota, inflammatory bowel disease and colorectal cancer. World J Gastroenterol 2022;28(30):4053–60. DOI: 10.3748/wjg.v28.i30.4053</mixed-citation><mixed-citation xml:lang="ru">Quaglio A.E.V., Grillo T.G., De Oliveira E.C.S. et al. Gut microbiota, inflammatory bowel disease and colorectal cancer. World J Gastroenterol 2022;28(30):4053–60. DOI: 10.3748/wjg.v28.i30.4053</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">22. Jin M., Shang F., Wu J. et al. Tumor-associated microbiota in proximal and distal colorectal cancer and their relationships with clinical outcomes. Front Microbiol 2021;12:727937. DOI: 10.3389/fmicb.2021.727937</mixed-citation><mixed-citation xml:lang="ru">Jin M., Shang F., Wu J. et al. Tumor-associated microbiota in proximal and distal colorectal cancer and their relationships with clinical outcomes. Front Microbiol 2021;12:727937. DOI: 10.3389/fmicb.2021.727937</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">23. Appunni S., Rubens M., Ramamoorthy V. et al. Emerging evidence on the effects of dietary factors on the gut microbiome in colorectal cancer. Front Nutr 2021;8:718389. DOI: 10.3389/fnut.2021.718389</mixed-citation><mixed-citation xml:lang="ru">Appunni S., Rubens M., Ramamoorthy V. et al. Emerging evidence on the effects of dietary factors on the gut microbiome in colorectal cancer. Front Nutr 2021;8:718389. DOI: 10.3389/fnut.2021.718389</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">24. Keller D.S., Windsor A., Cohen R., Chand M. Colorectal cancer in inflammatory bowel disease: review of the evidence. Tech Coloproctol 2019;23(1):3–13. DOI: 10.1007/s10151-019-1926-2</mixed-citation><mixed-citation xml:lang="ru">Keller D.S., Windsor A., Cohen R., Chand M. Colorectal cancer in inflammatory bowel disease: review of the evidence. Tech Coloproctol 2019;23(1):3–13. DOI: 10.1007/s10151-019-1926-2</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">25. Olén O., Erichsen R., Sachs M.C. et al. Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. Lancet 2020;395(10218):123–31. DOI: 10.1016/S0140-6736(19)32545-0</mixed-citation><mixed-citation xml:lang="ru">Olén O., Erichsen R., Sachs M.C. et al. Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. Lancet 2020;395(10218):123–31. DOI: 10.1016/S0140-6736(19)32545-0</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">26. Wang L., Yu K.C., Hou Y.Q. et al. Gut microbiome in tumorigenesis and therapy of colorectal cancer. J Cell Physiol 2023;238(1);94–108; DOI: 10.1002/jcp.30917</mixed-citation><mixed-citation xml:lang="ru">Wang L., Yu K.C., Hou Y.Q. et al. Gut microbiome in tumorigenesis and therapy of colorectal cancer. J Cell Physiol 2023;238(1);94–108; DOI: 10.1002/jcp.30917</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">27. Roth G.A., Mensah G.A., Johnson C.O. et al. Global burden of cardiovascular diseases and risk factors, 1990–2019 update from the GBD 2019 study. J Am Coll Cardiol 2020;76(25):2982–3021. DOI: 10.1016/j.jacc.2020.11.010</mixed-citation><mixed-citation xml:lang="ru">Roth G.A., Mensah G.A., Johnson C.O. et al. Global burden of cardiovascular diseases and risk factors, 1990–2019 update from the GBD 2019 study. J Am Coll Cardiol 2020;76(25):2982–3021. DOI: 10.1016/j.jacc.2020.11.010</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">28. Garg Y., Kanwar N., Chopra S. et al. Microbiome medicine: microbiota in development and management of cardiovascular diseases. Endocr Metab Immune Disord Drug Targets 2022;22(14):1344–56. DOI: 10.2174/1871530322666220624161712</mixed-citation><mixed-citation xml:lang="ru">Garg Y., Kanwar N., Chopra S. et al. Microbiome medicine: microbiota in development and management of cardiovascular diseases. Endocr Metab Immune Disord Drug Targets 2022;22(14):1344–56. DOI: 10.2174/1871530322666220624161712</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">29. Peng J., Xiao X., Hu M., Zhang X. Interaction between gut microbiome and cardiovascular disease. Life Sci 2018;214:153–7. DOI: 10.1016/j.lfs.2018.10.063</mixed-citation><mixed-citation xml:lang="ru">Peng J., Xiao X., Hu M., Zhang X. Interaction between gut microbiome and cardiovascular disease. Life Sci 2018;214:153–7. DOI: 10.1016/j.lfs.2018.10.063</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">30. Tang W.H.W., Li D.Y., Hazen S.L. Dietary metabolism, the gut microbiome, and heart failure. Nat Rev Cardiol 2019;16(3):137–54. DOI: 10.1038/s41569-018-0108-7</mixed-citation><mixed-citation xml:lang="ru">Tang W.H.W., Li D.Y., Hazen S.L. Dietary metabolism, the gut microbiome, and heart failure. Nat Rev Cardiol 2019;16(3):137–54. DOI: 10.1038/s41569-018-0108-7</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">31. Lu Y., Zhang Y., Zhao X. et al. Microbiota-derived short-chain fatty acids: implications for cardiovascular and metabolic disease. Front Cardiovasc Med 2022;9:900381. DOI: 10.3389/fcvm.2022.900381</mixed-citation><mixed-citation xml:lang="ru">Lu Y., Zhang Y., Zhao X. et al. Microbiota-derived short-chain fatty acids: implications for cardiovascular and metabolic disease. Front Cardiovasc Med 2022;9:900381. DOI: 10.3389/fcvm.2022.900381</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">32. Zhou X., Jin M., Liu L. et al. Trimethylamine N-oxide and cardiovascular outcomes in patients with chronic heart failure after myocardial infarction. ESC Heart Failure 2020;7(1):188–93. DOI: 10.1002/ehf2.12552</mixed-citation><mixed-citation xml:lang="ru">Zhou X., Jin M., Liu L. et al. Trimethylamine N-oxide and cardiovascular outcomes in patients with chronic heart failure after myocardial infarction. ESC Heart Failure 2020;7(1):188–93. DOI: 10.1002/ehf2.12552</mixed-citation></citation-alternatives></ref><ref id="B33"><label>33.</label><citation-alternatives><mixed-citation xml:lang="en">33. Sanchez-Gimenez R., Ahmed-Khodja W., Molina Y. et al. Gut microbiota-derived metabolites and cardiovascular disease risk: a systematic review of prospective cohort studies. Nutrients 2022;14(13):2654. DOI: 10.3390/nu14132654</mixed-citation><mixed-citation xml:lang="ru">Sanchez-Gimenez R., Ahmed-Khodja W., Molina Y. et al. Gut microbiota-derived metabolites and cardiovascular disease risk: a systematic review of prospective cohort studies. Nutrients 2022;14(13):2654. DOI: 10.3390/nu14132654</mixed-citation></citation-alternatives></ref><ref id="B34"><label>34.</label><citation-alternatives><mixed-citation xml:lang="en">34. Li J., Zhao F., Wang Y. et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome 2017;5(1):14. DOI: 10.1186/s40168-016-0222-x</mixed-citation><mixed-citation xml:lang="ru">Li J., Zhao F., Wang Y. et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome 2017;5(1):14. DOI: 10.1186/s40168-016-0222-x</mixed-citation></citation-alternatives></ref><ref id="B35"><label>35.</label><citation-alternatives><mixed-citation xml:lang="en">35. Zhen J., Zhou Z., He M. et al. The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases. Front Endocrinol (Lausanne) 2023;14:1085041. DOI: 10.3389/fendo.2023.1085041</mixed-citation><mixed-citation xml:lang="ru">Zhen J., Zhou Z., He M. et al. The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases. Front Endocrinol (Lausanne) 2023;14:1085041. DOI: 10.3389/fendo.2023.1085041</mixed-citation></citation-alternatives></ref><ref id="B36"><label>36.</label><citation-alternatives><mixed-citation xml:lang="en">36. Oniszczuk A., Oniszczuk T., Gancarz M., Szymańska J. Role of gut microbiota, probiotics and prebiotics in the cardiovascular diseases. Molecules 2021;26(4):1172. DOI: 10.3390/molecules26041172</mixed-citation><mixed-citation xml:lang="ru">Oniszczuk A., Oniszczuk T., Gancarz M., Szymańska J. Role of gut microbiota, probiotics and prebiotics in the cardiovascular diseases. Molecules 2021;26(4):1172. DOI: 10.3390/molecules26041172</mixed-citation></citation-alternatives></ref><ref id="B37"><label>37.</label><citation-alternatives><mixed-citation xml:lang="en">37. Sanchez-Rodriguez E., Egea-Zorrilla A., Plaza-Díaz J. et al. The gut microbiota and its implication in the development of atherosclerosis and related cardiovascular diseases. Nutrients 2020;12(3):605. DOI: 10.3390/nu12030605</mixed-citation><mixed-citation xml:lang="ru">Sanchez-Rodriguez E., Egea-Zorrilla A., Plaza-Díaz J. et al. The gut microbiota and its implication in the development of atherosclerosis and related cardiovascular diseases. Nutrients 2020;12(3):605. DOI: 10.3390/nu12030605</mixed-citation></citation-alternatives></ref><ref id="B38"><label>38.</label><citation-alternatives><mixed-citation xml:lang="en">38. Manolis A.A., Manolis T.A., Melita H., Manolis A.S. Gut microbiota and cardiovascular disease: symbiosis versus dysbiosis. Curr Med Chem 2022;29(23):4050–77. DOI: 10.2174/0929867328666211213112949</mixed-citation><mixed-citation xml:lang="ru">Manolis A.A., Manolis T.A., Melita H., Manolis A.S. Gut microbiota and cardiovascular disease: symbiosis versus dysbiosis. Curr Med Chem 2022;29(23):4050–77. DOI: 10.2174/0929867328666211213112949</mixed-citation></citation-alternatives></ref><ref id="B39"><label>39.</label><citation-alternatives><mixed-citation xml:lang="en">39. Jin L., Shi X., Yang J. et al. Gut microbes in cardiovascular diseases and their potential therapeutic application. Protein Cell 2021;12(5):346–59. DOI: 10.1007/s13238-020-00785-9</mixed-citation><mixed-citation xml:lang="ru">Jin L., Shi X., Yang J. et al. Gut microbes in cardiovascular diseases and their potential therapeutic application. Protein Cell 2021;12(5):346–59. DOI: 10.1007/s13238-020-00785-9</mixed-citation></citation-alternatives></ref></ref-list></back></article>
